Skip to content
Menu

Relay Therapeutics, Inc. RLAY

Full chart Compare
Set alert

Price alert · RLAY

All alert types
16.12 USD +0.21 (+1.32%)

Regular-session close

16.12 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

15.17 Day range 16.32
6.28 52-week range 21.27
YTD
+90.54%
1 year
+152.66%

5D -1.76 (-9.96%)

161718FriMonTueWedThu15.91
Market cap
3.56B
Revenue (ttm)
10.35M
EPS (ttm)
-1.50
Shares out
220.96M
Forward P/E
-10.26
YTD return
+90.54%
1-year return
+152.66%
50-day average
18.18
200-day average
15.70
Enterprise value
2.69B
Volume
3.98M
Avg volume
2.92M
Open
15.59
Previous close
15.91
Day's range
15.17 – 16.32
52-week range
6.28 – 21.27
Beta
1.74
Analysts
Strong Buy
Price target
28.25 (+75.2%)
Earnings date
Feb 25, 2027

Key statistics

Price / sales
344.14
Price / book
4.32
Free cash flow
-117.45M
Total cash
848.64M
Total debt
27.03M
Return on equity
-41.16%
Short % of float
22.96%

Fundamental scorecard

6 of 25 checks passed on RLAY’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
RLAY Revenue — quarterly 0
RLAY Net income — quarterly -81.75M
RLAY EPS — quarterly -0.37

Earnings

RLAY recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 2026-0.38———
Nov 4, 2026Sep 30, 2026-0.39676-0.37+0.03+6.74%
Aug 6, 2026Jun 30, 2026-0.39107-0.41-0.02-4.84%
May 5, 2026Mar 31, 2026-0.35-0.41-0.06-17.14%
Feb 26, 2026Dec 31, 2025-0.38-0.32+0.06+15.79%
Nov 6, 2025Sep 30, 2025-0.39-0.43-0.04-10.26%

Upgrades / downgrades

RLAY analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2026Jones TradingmainBuyBuy
Aug 20, 2026HC Wainwright & Co.mainBuyBuy
Aug 14, 2026JP MorganmainOverweightOverweight
Aug 10, 2026CitizensmainMarket OutperformMarket Outperform
Aug 7, 2026BarclaysmainOverweightOverweight
Jul 21, 2026Goldman SachsmainBuyBuy

About Relay Therapeutics, Inc.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
relaytx.com

News

Your note

Sign in to keep a note on RLAY — it syncs with the Stock Master app.

Insider holders

RLAY insider holders
InsiderRelationLatest transactionDateShares held
ADAMS BRIAN ROfficerSaleJul 28, 2025371,472
BERGSTROM DONALD A.OfficerSaleSep 7, 2026399,130
CATINAZZO THOMAS JChief Financial OfficerSaleOct 5, 2026105,134
PATEL SANJIV NARATANBHAIChief Executive OfficerSaleOct 6, 20261,358,200
RAHMER PETER JOfficerSaleAug 25, 2026223,657
SVF PAULING CAYMAN LTDBeneficial Owner of more than 10% of a Class of SecuritySaleAug 24, 20260

Institution ownership

RLAY institution ownership
Holder% heldSharesValueReported
FMR, LLC10.97%24,239,485390.74MSep 29, 2026
SB Investment Advisers (UK) LTD9.91%21,904,963353.11MSep 29, 2026
T. Rowe Price Investment Management, Inc.8.09%17,868,157288.03MSep 29, 2026
Blackrock Inc.7.56%16,700,112269.21MSep 29, 2026
Casdin Capital, LLC7.26%16,035,240258.49MSep 29, 2026
Perceptive Advisors Llc5.76%12,730,336205.21MSep 29, 2026

Fund ownership

RLAY fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.08%6,800,083109.62MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.20%4,863,23678.40MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.14%4,719,92476.09MSep 29, 2026
Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total 1.18%2,617,29742.19MSep 29, 2026
Fidelity Select Portfolios-Select Health Care Portfolio0.94%2,080,00033.53MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.88%1,943,78831.33MJun 29, 2026